China's CStone bags $260M Series B for ambitious I/O work, expanding its list of marquee investors
The era of immuno-oncology combos has arrived, and China’s going to play a big role — or so says the backers of CStone Pharmaceuticals, a fast …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
